Iannone Robert 4

What Happened
Robert Iannone, EVP & Global Head of R&D and Chief Medical Officer at Jazz Pharmaceuticals (JAZZ), was granted 14,822 restricted stock units (RSUs) on February 26, 2026. The Form 4 reports the award as an acquisition at $0.00 per unit (standard for equity awards); no cash was paid. This is an award (transaction code A), not an open-market purchase or sale.

Key Details

• Transaction date: 2026-02-26; Form 4 filed: 2026-03-02 (timely filing).
• Award: 14,822 restricted stock units (RSUs) reported at $0.00 per unit.
• Plan: Granted under the Issuer’s 2011 Equity Incentive Plan.
• Vesting: RSUs vest in equal annual installments over four years measured from a vesting commencement date of March 5, 2026 — 1/4 vests on March 5, 2027, and the remainder vests in equal annual installments over the next three years.
• Shares owned after transaction: Not specified in the filing.
• Transaction code: A (award/grant).

Context
Restricted stock units are a form of equity compensation that convert to ordinary shares only as they vest; they do not indicate an immediate sale or purchase in the market. Such awards are routine for executive compensation and should be interpreted as part of long-term incentive pay rather than a direct market signal.